Rep. Kevin Hern Sells Off Shares of Medtronic PLC (NYSE:MDT)

Posted by Defense World Staff on Apr 7th, 2026

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Medtronic PLC (NYSE:MDT). In a filing disclosed on April 03rd, the Representative disclosed that they had sold between $15,001 and $50,000 in Medtronic stock on March 20th. The trade occurred in the Representative’s “HERN FAMILY REVOCABLE TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Exact Sciences (NASDAQ:EXAS) on 3/24/2026.
Sold $50,001 – $100,000 in shares of Prologis (NYSE:PLD) on 3/20/2026.
Sold $15,001 – $50,000 in shares of T. Rowe Price Group (NASDAQ:TROW) on 3/20/2026.
Sold $500,001 – $1,000,000 in shares of Smartstop Self Storage REIT (NYSE:SMA) on 3/18/2026.
Sold $500,001 – $1,000,000 in shares of Texas Instruments (NASDAQ:TXN) on 3/18/2026.
Sold $50,001 – $100,000 in shares of BlackRock MuniAssets Fund (NYSE:MUA) on 3/17/2026.
Sold $15,001 – $50,000 in shares of Cognizant Technology Solutions (NASDAQ:CTSH) on 3/17/2026.
Sold $15,001 – $50,000 in shares of Invesco (NYSE:IVZ) on 3/17/2026.
Sold $15,001 – $50,000 in shares of Becton, Dickinson and Company (NYSE:BDX) on 3/17/2026.
Sold $15,001 – $50,000 in shares of Comcast (NASDAQ:CMCSA) on 3/17/2026.

Medtronic Stock Down 0.4%

Shares of NYSE MDT opened at $86.27 on Tuesday. The stock has a market cap of $110.77 billion, a P/E ratio of 24.03, a PEG ratio of 2.24 and a beta of 0.75. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33. The business’s fifty day simple moving average is $94.18 and its 200-day simple moving average is $96.19.

Medtronic (NYSE:MDT – Get Free Report) last announced its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period last year, the firm earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts predict that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be paid a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 3.3%. The ex-dividend date is Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is presently 79.11%.

Insider Buying and Selling

In related news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.26% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Leerink Partners reissued an “outperform” rating and issued a $119.00 target price on shares of Medtronic in a report on Tuesday, March 10th. William Blair raised Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. Piper Sandler dropped their target price on Medtronic from $105.00 to $91.00 and set a “neutral” rating on the stock in a report on Wednesday, April 1st. CICC Research assumed coverage on Medtronic in a report on Friday, January 30th. They issued an “outperform” rating on the stock. Finally, JPMorgan Chase & Co. dropped their target price on Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $109.85.

Check Out Our Latest Stock Analysis on MDT

Hedge Funds Weigh In On Medtronic

Hedge funds have recently made changes to their positions in the company. Artisan Partners Limited Partnership grew its holdings in shares of Medtronic by 2.6% during the third quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company’s stock worth $117,579,000 after buying an additional 31,314 shares during the last quarter. SageView Advisory Group LLC lifted its position in Medtronic by 164.8% in the third quarter. SageView Advisory Group LLC now owns 24,204 shares of the medical technology company’s stock valued at $2,305,000 after purchasing an additional 15,062 shares during the period. CSM Advisors LLC lifted its position in Medtronic by 13.2% in the third quarter. CSM Advisors LLC now owns 285,260 shares of the medical technology company’s stock valued at $27,169,000 after purchasing an additional 33,167 shares during the period. UMB Bank n.a. lifted its position in Medtronic by 65.8% in the third quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock valued at $13,170,000 after purchasing an additional 54,898 shares during the period. Finally, Applied Finance Capital Management LLC acquired a new stake in Medtronic in the third quarter valued at about $1,308,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Medtronic Company Profile

(Get Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).